MedTrace Logo

Plasma Concentration of Somatostatin and Endocannabinoids After GA and RA in Upper Extremity Trauma Surgery

NCT04040738 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-11-05

No results posted yet for this study

Summary

The application of RA can decrease the central sensitization and chronic pain after trauma surgery. The plasma concentrations of somatostatin and fatty acid amides were not studied up to this time in this kind of settings, so investigators believe that this is the first work that shows how upper extremity nerve blockade changes the plasma concentration of somatostatin and fatty acid amides in upper limb surgery in trauma patients.

Conditions

  • Postoperative Pain
  • Arm Injury

Interventions

PROCEDURE

Upper extremity surgery under general anaesthesia

Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance

PROCEDURE

Upper extremity surgery under regional anaesthesia

Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Principal Investigators

  • Robert G Almasi, PhD.Habil. · University of Pecs, Medical School, Clinical Centre, Pain Medicine Dept.of Anesth Int Care

  • Zsofia Kriszta, MD. · University of Pecs, Medical School, Clinical Centre, Dept.of Anesth Int Care

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-05
Primary Completion
2021-11-20
Completion
2022-01-10

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04040738 on ClinicalTrials.gov